Open letter to CEPI Board Members: Revise CEPI's access policy

Research and development

Latest news

Video |

22 March 2019

TB: New drugs, new hope

Technical brief |

11 March 2019

MSF Access Campaign analysis of the MPP Licence Agreement with AbbVie for glecaprevir/pibrentasvir (G/P)

Opinion article |

07 March 2019

Norway has invested 200 million euros in epidemic preparedness, but are they getting what they’re paying for?

Technical brief |

07 March 2019

MPP licence agreement with AbbVie for glecaprevir/pibrentasvir

Press release |

20 February 2019

Novartis secures FDA innovation prize for 30-year-old drug

Most recent Priority Review Voucher is a reminder of why Congress should reform the US government program to only reward companies for developing new and affordable drugs and vaccines for neglected diseases

Letter |

11 February 2019

Malaysia

Malaysia’s compulsory licence for sofosbuvir is a positive step for public health and innovation

Médecins Sans Frontières (MSF) Access Campaign wrote a letter of support to the Malaysian government commending the issuance of a government use licence to enable access to an affordable version of the hepatitis C drug sofosbuvir. The licence issued by Malaysia on 20 September 2017 eliminated patent barriers and has resulted in the scale-up of treatment in public hospitals throughout the country.

Technical brief |

08 February 2019

India

Opposing patent application for bedaquiline formulation in India

Video |

08 February 2019

TB survivors challenge J&J's patent on TB drug in India

Phumeza and Nandita suffered permanent hearing loss because of toxic drugs used to treat their drug-resistant TB.

Now they’re working to ensure that this doesn’t happen to anyone else.

Press release |

07 February 2019

TB activists for first time challenge TB drug patent in India

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug bedaquiline.

Statement |

31 January 2019

144th WHO EB: Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Antimicrobial resistance

WHO Executive Board, 144th Session, January 2019
MSF Statement: Agenda item 5.8.1 (EB144/19) – Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Antimicrobial resistance

Statement |

30 January 2019

144th WHO EB: Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Ending tuberculosis

WHO Executive Board, 144th Session, January 2019
MSF Statement: Agenda item 5.8.3 (EB144/21) – Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Ending tuberculosis

Statement |

29 January 2019

144th WHO EB: Medicines, vaccines and health products - Access to medicines and vaccines

WHO Executive Board, 144th Session, January 2019
MSF Statement: Agenda item 5.7.1 (EB144/17) – Medicines, vaccines and health products: Access to medicines and vaccines